Qiming Corporate GP VI, Ltd. filed a Form 4 with the SEC disclosing dispositions of Alamar Biosciences, Inc. common stock across October 27 and October 28, 2026, covering sales across four record-holding funds.

Key Highlights

  • Reporting person: Qiming Corporate GP VI, Ltd., identified as a 10% owner and director-affiliated entity of Alamar Biosciences, Inc. (NASDAQ:ALMR).
  • Transaction type: All reported transactions carry code "S" (sale) and are designated as dispositions of common stock.
  • October 27 sales: Multiple lots of common stock were disposed of across four funds at weighted average prices of $30.33, $31.33, and $31.88 per share, according to the filing.
  • October 28 sales: Additional lots were disposed of at weighted average prices of $32.47 and $33.11 per share, according to the filing.
  • Remaining holdings: Following all reported transactions, the four funds held approximately 164,191, 6,101,979, 1,423,781, and 1,704,596 shares respectively, as disclosed in the filing.
  • Seven reporting persons: The filing lists seven entities, including Qiming Corporate GP VI, Ltd., Qiming Managing Directors Fund VI, L.P., Qiming Venture Partners VI, L.P., Qiming GP VIII, LLC, Qiming Venture Partners VIII Investments, LLC, Qiming GP VIII-HC, LLC, and Qiming Venture Partners VIII-HC, L.P.

Qiming-Affiliated Funds Reduce Positions in Alamar Biosciences Over Two Days

According to the filing, Qiming Corporate GP VI, Ltd. reported sales of Alamar Biosciences, Inc. common stock on October 27 and October 28, 2026. The shares subject to these transactions were held of record across four separate funds: Qiming Managing Directors Fund VI, L.P.; Qiming Venture Partners VI, L.P.; Qiming Venture Partners VIII Investments, LLC; and Qiming Venture Partners VIII-HC, L.P. Alamar Biosciences, Inc. is a biosciences company listed on NASDAQ under the ticker ALMR.

The filing discloses that all prices reported are weighted average prices, and that shares were sold across multiple transactions within each stated price range. For the October 27 transactions, the filing describes actual per-share price ranges of $29.76 to $30.67 (weighted average $30.33), $30.765 to $31.75 (weighted average $31.33), and $31.76 to $31.955 (weighted average $31.88). For the October 28 transactions, the filing describes ranges of $31.87 to $32.865 (weighted average $32.47), with the fifth price range for the $33.11 weighted average appearing partially in the filing. The reporting person stated it will provide full detail on each separate transaction price upon request by the issuer, any security holder, or SEC staff.

The filing further discloses the ownership structure underlying these transactions. Qiming Corporate GP VI, Ltd. serves as general partner of Qiming Managing Directors Fund VI, L.P., and as indirect general partner of Qiming Venture Partners VI, L.P. through one intermediary. The filing states that Qiming Corporate disclaims beneficial ownership of shares held by those funds, except to the extent of its proportionate pecuniary interest. Similarly, Qiming GP VIII, LLC and Qiming GP VIII-HC, LLC are disclosed as the respective indirect general partner and general partner of the remaining two funds, each with analogous disclaimers of beneficial ownership.

What Was Disclosed

Qiming Corporate GP VI, Ltd. and six affiliated entities reported dispositions of Alamar Biosciences common stock on October 27 and October 28, 2026, across four record-holding funds, with all transactions coded as sales and ownership forms listed as indirect.